GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis AS (OTCPK:NVZMY) » Definitions » Debt-to-EBITDA

Novonesis AS (Novonesis AS) Debt-to-EBITDA : 1.85 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Novonesis AS Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Novonesis AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $464 Mil. Novonesis AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $667 Mil. Novonesis AS's annualized EBITDA for the quarter that ended in Dec. 2023 was $610 Mil. Novonesis AS's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 1.85.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Novonesis AS's Debt-to-EBITDA or its related term are showing as below:

NVZMY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.09   Med: 0.44   Max: 1.81
Current: 1.81

During the past 13 years, the highest Debt-to-EBITDA Ratio of Novonesis AS was 1.81. The lowest was 0.09. And the median was 0.44.

NVZMY's Debt-to-EBITDA is ranked better than
55.16% of 1222 companies
in the Chemicals industry
Industry Median: 2.225 vs NVZMY: 1.81

Novonesis AS Debt-to-EBITDA Historical Data

The historical data trend for Novonesis AS's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis AS Debt-to-EBITDA Chart

Novonesis AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.67 0.11 0.09 1.12 1.41

Novonesis AS Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.53 0.09 0.12 0.08 1.85

Competitive Comparison of Novonesis AS's Debt-to-EBITDA

For the Specialty Chemicals subindustry, Novonesis AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis AS's Debt-to-EBITDA Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis AS's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Novonesis AS's Debt-to-EBITDA falls into.



Novonesis AS Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Novonesis AS's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(464.242 + 667.174) / 800.462
=1.41

Novonesis AS's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(464.242 + 667.174) / 610.404
=1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Novonesis AS  (OTCPK:NVZMY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Novonesis AS Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Novonesis AS's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis AS (Novonesis AS) Business Description

Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novozymes is the world leader in industrial enzymes. In recent years, the company has expanded into micro-organisms, primarily for agricultural markets. The firm supplies five major industry groups: household care, food and beverages, bioenergy, agriculture and feed, and technical and pharma. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark.

Novonesis AS (Novonesis AS) Headlines

From GuruFocus

Novozymes A/S's Dividend Analysis

By GuruFocus Research 10-19-2023

2 Holdings to Reduce Based on Analyst Recommendations

By Alberto Abaterusso Alberto Abaterusso 11-06-2019

Not Just Yogurt Anymore

By PRNewswire 10-26-2023